Frontotemporal Dementia, Pick's Disease
Conditions
Keywords
Social Cognition, Oxytocin
Brief summary
Investigations into the components of cognition damaged in frontotemporal dementia (FTD) demonstrate that patients with FTD show deficits in facial and verbal expression recognition, lack insight into what others think or might do (theory of mind skills), and in decision making tasks requiring processing of positive versus negative feedback. These cognitive functions are thought to be critical for appropriate social behavioural regulation (Blair, 2003). Recent studies in animal models and humans suggest that the neuropeptide oxytocin is an important mediator of social behavior and that oxytocin may facilitate emotion recognition, theory of mind processing, and prosocial behaviors (Donaldson and Young, 2008). Together, these findings suggest that upregulation of oxytocin dependent mechanisms of social and emotional cognition may be a valuable treatment approach in patients with FTD. The aim of this study is to determine how administration of intranasal oxytocin to patients with frontotemporal dementia affects behavior and processing of specific types of social and emotional information.The investigators' hypothesis is that oxytocin administration will improve emotional and social cognitive deficits in patients with FTD, resulting in improved decision making and behaviour.
Interventions
DRUGintranasal oxytocin
Participants will receive 24 IU of oxytocin or placebo (Salinex saline nasal spray) intranasally 30 minutes prior to completing the experimental tasks. Two weeks later participants will return for a second visit and receive the alternate drug (either intranasal oxytocin or Salinex) prior to completing the experimental tasks.
Sponsors
The Alzheimer Society London and Middlesex
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
30 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis of probable Frontotemporal Dementia or Pick's disease * Caregiver available to participate in all study visits
Exclusion criteria
* Severe language or memory deficits that preclude completion of the cognitive tasks * Females who are pregnant or breastfeeding (a pregnancy test will be done on females who have not completed menopause) * Uncontrolled hypertension * Bradycardia (rate \<50 bpm) or tachycardia (rate \> 100 bpm) * Current use of prostaglandins * Use of any investigational or experimental drug or device within the last 60 days prior to screening or within 5 half-lives of the experimental drug , whichever is longer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Performance on Emotion Recognition Tasks | Day of treatment |
Secondary
| Measure | Time frame |
|---|---|
| Behavioural Ratings of Emotional Sensitivity and Repetitive Behaviours | One week following treatment |
| Side effects | 1 week after treatment |
Countries
Canada
Outcome results
None listed